Separately, GLP-1 drugs appear to reduce alcohol cravings: a May 2026 Lancet trial found semaglutide cut heavy drinking days by 41% versus 26% on placebo in adults with alcohol use disorder and obesity
This restores their ability to burn fat into energy and to maintain a proper environment within mitochondria, and restores proper cell division behavior to TMLHE-deficient neural stem cells
Lyzenga-Dean highlights several drawbacks: "These drugs are expensive and rarely covered by insurance for folks who don't meet strict criteria, usually advanced diabetes." Additionally, these medications often require lifelong use to maintain results and can cause serious digestive side effects
Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Vilsboll T, Knop FK, Holst JJ
BLIV MEDLEM Indmeld din forening her Flg os p Facebook her .
Used by many of our weight loss patients as a between-IV booster on a GLP-1 protocol